Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis.
Dionysia D FermeliTheodoros D MarantosAlexandros-Leonidas D LiarakosGeorge D PanayiotakopoulosVasileios K DedesGeorgios I PanoutsopoulosPublished in: Folia medica (2021)
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- multidrug resistant
- acinetobacter baumannii
- pulmonary tuberculosis
- methicillin resistant staphylococcus aureus
- infectious diseases
- hiv aids
- early onset
- chronic kidney disease
- physical activity
- combination therapy
- emergency department
- hepatitis c virus
- cystic fibrosis
- drug induced
- risk assessment
- social media
- health information
- electronic health record
- human health
- climate change
- smoking cessation
- hiv infected